EGFR and non-small cell lung carcinoma: In phase I trials in advanced solid tumors, NSCLC with EGFR mutation, and GC, retlirafusp alfa induced medium ORRs of 17.8%,394 16.7%,395 and 19.4%,396 but an impressive ORR of 44.2% was observed in the PD-L1+ NSCLC cohort.397 The efficacy of retlirafusp alfa needs further confirmation since its design is similar to bintrafusp alfa, which was removed from the pipeline of Merck, owing to its inferiority compared to pembrolizumab in a phase III trial.398 Ivonescimab is a symmetric IgG1 PD-1×VEGF bsAb.